The 2013 WHO guidelines for antiretroviral therapy: Evidence-based recommendations to face new epidemic realities

Current Opinion in HIV and AIDS

Volumn 8, Issue 6, 2013, Pages 528-534

  Doherty, Meg ^a   Ford, Nathan ^a   Vitoria, Marco ^a   Weiler, Gundo ^a   Hirnschall, Gottfried ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

antiretroviral therapy; Public health approach; Simplification; Strategic use

Indexed keywords

EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; TENOFOVIR; ZIDOVUDINE;

BIRTH DEFECT; CD4 LYMPHOCYTE COUNT; CONFUSION; COST CONTROL; DECENTRALIZATION; DEVELOPING COUNTRY; DISEASE COURSE; DRUG EXPOSURE; DRUG SAFETY; EPIDEMIC; EVIDENCE BASED PRACTICE; FOLLOW UP; HEALTH CARE DELIVERY; HEALTH SERVICE; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; LACTIC ACIDOSIS; LIPODYSTROPHY; LONG TERM EXPOSURE; MEN WHO HAVE SEX WITH MEN; NEURAL TUBE DEFECT; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; SCALE UP; SELF EVALUATION; SYSTEMATIC REVIEW; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

ANTIVIRAL AGENTS; GUIDELINES AS TOPIC; HUMANS; VIRUS DISEASES; WORLD HEALTH ORGANIZATION;

EID: 84886088726     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000008     Document Type: Review

References (48)

1. Anon. AIDS epidemic update. Geneva: UNAIDS/World Health Organization; 2002.
2. Anon. Global update on HIV treatment 2013: results, impact and opportunities. World Health Organization/UNAIDS/UNICEF; July 2013.
3. Johnson LF, Mossong J, Dorrington RE, et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med 2013; 10:e1001418.
4. Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from uganda. Ann Intern Med 2011; 155:209-216.
5. Wood E, Braitstein P, Montaner JS, et al. Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa. Lancet 2000; 355:2095-2100.
6. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
7. Schwartlander B, Stover J, Hallett T, et al. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet 2011; 377:2031-2041.
8. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and preexposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012; 4:151ra125.
9. Vitoria M, Vella S, Ford N. Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challenges. Curr Opin HIV AIDS 2013; 8:12-18.
10. Gupta S, Granich R, Suthar AB, et al. Global policy review of ART eligibility criteria for treatment and prevention of HIV and TB in adults, pregnant women, and serodiscordant couples: ART recommendations by national guidelines. J Acquir Immune Defic Syndr 2013; 62 (3):e87-e97.
11. Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 2011; 25:2301-2304.
12. Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving art at baseline in the smart study. J Infect Dis 2008; 197:1133-1144.
13. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-1363.
14. Chene G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362:679-686.
15. Writing Committee for the CASCADE Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med 2011; 171:1560-1569.
16. Cain LE, Logan R, Robins JM, et al. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med 2011; 154:509-515.
17. Baker JV, Peng G, Rapkin J, et al. Cd4 count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22:841-848.
18. Moore RD, Gebo KA, Lucas GM, Keruly JC. Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status. Clin Infect Dis 2008; 47:1102-1104.
19. Schouten EJ, Jahn A, Midiani D, et al. Prevention of mother-to-child transmission of HIV and the health-related millennium development goals: time for a public health approach. Lancet 2011; 378:282-284.
20. Subbaraman R, Chaguturu SK, Mayer KH, et al. Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis 2007; 45:1093-1101.
21. McComsey G, Lonergan JT. Mitochondrial dysfunction: patient monitoring and toxicity management. J Acquir Immune Defic Syndr 2004; 37 (Suppl 1): S30-35.
22. Wangai M, Mwanthi MA, Mbugua G, Wangai P. Adverse drug reactions associated with highly active antiretroviral therapy at the Mbagathi District Hospital, Nairobi, Kenya. 6th IAS Conference on HIV Pathogenesis and Treatment: Abstract CDB490.
23. Shubber Z, Calmy A, Andrieux-Meyer I, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS 2013; 27 (9):1403-1412.
24. Raatz H. Adverse events associated with tenofovir use: a systematic review and meta-analysis. 2012 (web annex to guidelines 2013).
25. Ford N, Shubber Z, Hill A, et al. Comparative efficacy of lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials. AIDS (in press).
26. Technical Update on Treatment Optimization. Pharmacological equivalence and clinical interchangeability of lamivudine and emtricitabine: a review of current literature. Geneva: WHO; 2012.
27. Technical Update on Treatment Optimization. Use of efavirenz during pregnancy: a public health perspective. Geneva: WHO; 2012.
28. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010; 363:1510-1520.
29. Violari A, Lindsey JC, Hughes MD, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 2012; 366:2380-2389.
30. Mugglin C, Althoff K, Wools-Kaloustian K, Sterne J, et al., and IeDEA and ART-CC Collaborations. Immunodeficiency at the start of ART: global view. 19th Conference on Retroviruses and Opportunistic Infections, Washington, 5-8 March 2012 [Abstract 26].
31. Hensen B, Baggaley R, Wong VJ, et al. Universal voluntary HIV testing in antenatal care settings: a review of the contribution of provider-initiated testing and counselling. Trop Med Int Health 2012; 17:59-70.
32. Orne-Gliemann J, Balestre E, Tchendjou P, et al. Increasing HIV testing among male partners. The Prenahtest ANRS 12127 multicountry randomised trial. AIDS 2013; 27:1167-1177.
33. Sabapathy K, Van den Bergh R, Fidler S, et al. Uptake of home-based voluntary HIV testing in sub-Saharan Africa: a systematic review and metaanalysis. PLoS Med 2012; 9:e1001351
34. MacPherson P. Home assessment and initiation of ART following HIV selftesting: a cluster-randomized trial to improve linkage to ART in Blantyre, Malawi. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, 3-6 March 2013 [Paper #95lb].
35. Mugglin C, Estill J, Wandeler G, et al. Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health 2012; 17:1509-1520.
36. Mugglin C, Wandeler G, Estill J, et al. Retention in care of HIV-infected children from HIV test to start of antiretroviral therapy: systematic review. PLoS One 2013; 8:e56446.
37. Kranzer K, Govindasamy D, Ford N, et al. Quantifying and addressing losses along the continuum of care for people living with HIV infection in sub-Saharan Africa: a systematic review. J Int AIDS Soc 2012; 15:17383.
38. Centers for Disease Control and Prevention (CDC). Impact of an innovative approach to prevent mother-to-child transmission of HIV-Malawi, July 2011- September 2012. MMWR Morb Mortal Wkly Rep 2013; 62:148-151.
39. Fairall L, Bachmann MO, Lombard C, et al. Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial. Lancet 2012; 380:889-898.
40. Kredo T, Ford N, Adeniyi FB, Garner P. Decentralising HIV treatment in middle- and low-income countries. Cochrane Database Syst Rev 2012; 7:Cd009987
41. Jaffar S, Amuron B, Foster S, et al. Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, Southeast Uganda: a cluster-randomised equivalence trial. Lancet 2009; 374:2080-2089.
42. Kerschberger B, Hilderbrand K, Boulle AM, et al. The effect of complete integration of HIV and TB services on time to initiation of antiretroviral therapy: a before-after study. PLoS One 2012; 7:e46988. Observational study using advanced statistical analysis to demonstrate the benefit of integration of TB and HIV services.
43. Suthar AB, Hoos D, Beqiri A, et al. Integrating antiretroviral therapy into antenatal care and maternal and child health settings: a systematic review and meta-analysis. Bull World Health Organ 2013; 91:46-56.
44. Wood E, Hogg RS, Harrigan PR, Montaner JS. When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. Lancet Infect Dis 2005; 5:407-414.
45. Anon. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: laboratory testing. Department of Health and Human Services website. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescent GL.pdf.
46. Muessig KE, Smith MK, Powers KA, et al. Does art prevent HIV transmission among MSM? AIDS 2012; 26:2267-2273.
47. Kato M, Granich R, Duc Bui D, et al. The potential impact of expanding antiretroviral therapy and combination prevention in Vietnam: towards elimination of HIV transmission. J Acquir Immune Defic Syndr 2013; May 24.[Epub ahead of print]
48. Charlebois ED, Das M, Porco TC, Havlir DV. The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in San Francisco. Clin Infect Dis 2011; 52:1046-1049.